2-[[2-(N-isobutyl-N-methyl)amino] benzylsulfinyl]benzimidazole as antomicrobial agent against Helicobacter pylori

Abstract: 2-[[2-(N-Isobutyl-N-methyl)amino]benzylsulfinyl]benzimidazole is effective for treating or preventing Helicobacter infections by administration to patients suffering from the infections.

Description: The present invention relates to a novel use of 2-[[2-(N-isobutyl-N-methyl)amino]benzylsulfinyl]benzimidazole for the manufacture of an antimicrobial agent which is effective to inactivate Helicobacter pylori (which is formerly named Campylobacter pylori) and therefore is effective to treat or prevent infections caused by Helicobacter pylori. US-A-5 013 743 (corresponding to Japanese Patent Provisional Publication No. 3-173817) discloses that pyridine derivatives having a specific formula such as 2-(2-pyridyl)methylsulfinylbenzimidazole are effective to inactivate Campylobacter pylori. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Mar. 1991, p.490-496 describes that lansoprazole and omeprazole have antimicrobial activity against Helicobacter pylori. Japanese Patent Provisional Publication No. 3-161440 (published on July 11, 1991) discloses that condensed imidazole derivatives having a benzopyran, benzothiopyran, tetrahydroquinoline, or indoline ring are effective to inactivate Campylobacter pylori. US-A-5 093 342 discloses that 5-methoxy-2[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole is effective for treating infectious diseases caused by Campylobacter pylori. WO89/03219 (published on April 20, 1989, which corresponds to US-A-5 196 205) discloses that a bismuth compound is effective to treat infections caused by Campylobacter pylori. Further, a number of studies concerning relationship between Helicobacter pylori and peptic ulcer or gastritis have been reported. For instance, "Advance of Medical Science (in Japanese)", Vol. 159, No. 10, 1991, pp. 795 is mentioned. There is a report suggesting a relationship between Helicobacter pylori and recurrence of duodenal ulcer. GB-A-21 63 747 discloses a condensed imidazole derivative which is effective as an anti-ulcer agent, but is silent with respect to antimicrobacterial activity against to Helicobacter pylori. Japan. J. Pharmacol., 55 , 1991, 477-491, discloses the gastroprotective activity of 2-[[2-(N-isobutyl-N-methyl)amino]benzylsulfinyl]benzimidazole in the treatment of peptic ulcer. An object of the present invention is to provide an antimicrobial agent against Helicobacter pylori. The invention provides a use of 2-[[2-(N-isobutyl-N-methyl)amino]benzylsulfinyl]benzimidazole for the manufacture of a medicament for treating or preventing infections caused by Helicobacter pylori. This compound is used by administering to a patient suffering the infections in an amount sufficient for the treatment or prevention of the infections. The invention also provides a use of 2-[[2-(N-isobutyl-N-methyl)amino]benzylsulfinyl]benzimidazole for the manufacture of a medicament for inactivating Helicobacter pylori. For this purpose, the compound is brought into contact with Helicobacter pylori. The 2-[[2-(N-isobutyl-N-methyl)amino]benzylsulfinyl]benzimidazole is described in the aforementioned GB-A-21 63 747, and per se is known. This compound can be used in the form of a pharmaceutically acceptable salt such as sodium or potassium salt. The antimicrobacterial activity of the instant compound against Helicobacter pylori is shown by the following experimental data. Experimental 1 (1) Test compound: 2-[[2-(N-isobutyl-N-methyl)amino]benzylsulfinyl]benzimidazole dissolved in dimethylsulfoxide (DMSO) to give a solution of 80,000 µg/mL, and diluted by two-step dilution (2) MIC measurement: MIC(minimal inhibitory concentration) was determined by the following agar plate dilution method defined by Chemotherapy Society of Japan (Chemotherapy, vol. 29, 76-77(1991): The solution of test compound (100 µL) was placed on a glass plate (diameter: 9 cm). Into the solution was placed 9.9 mL of Brucella Broth (BBL) containing 10% of horse lysed blood, to give a plate agar medium for the measurement. The bacterial suspension of Helicobacter pylori was adjusted to have turbidity equivalent to McFarland standard 0.5 (10 8 cfu/mL) and it was diluted with a sterile saline to give a bacterial suspension of 10 7 cfu/mL. The bacterial suspension was inoculated on the plate agar medium containing the test compound using a microplanter. The medium was incubated at 35°C for 6 days in 15% carbon dioxide gas. The MIC (µg/mL) was determined by amount of growth. It was observed that MIC of the test compound (2-[[2-(N-isobutyl-N-methyl)amino]benzylsulfinyl]benzimidazole) showed MIC of 12.5 µg/mL. Accordingly, antimicrobial activity of the compound against Helicobacter pylori was confirmed. Experimental 2 (1) Test strain: juvenile strains of Standard strains (ATCC 43526, ATCC 43579, ATCC 43629, and NCTC 11637), two subcultured strains (Wild 1 & Wild 2). (2) Test compound: (1) 2-[[2-(N-isobutyl-N-methyl) amino]benzylsulfinyl]benzimidazole dissolved and diluted as in Experimental 1 (2) Omeprazole prepared in Laboratories of Nippon Chemiphar Co., Ltd., which was dissolved and diluted as in Experimental 1 (3) Cimetidine purchased from Sigma Corporation, which was dissolved and diluted as in Experimental 1 (4) Famotidine purchased from Sigma Corporation, which was dissolved and diluted as in Experimental 1 (3) MIC measurement: the same manner as in Experimental 1 The results of the observation are shown in Table 1. Strain MIC (µg/mL) Compound(1) Omeprazole Cimetidine Famotidine ATCC 43526 25 12.5 800 >800 ATCC 43579 25 12.5 800 800 ATCC 43629 12.5 12.5 800 800 NCTC 11637 25 50 - - Wild 1 50 50 - - Wild 2 50 50 - - In Table 1, "-" means that no test was done. As is apparent from the data set forth in Table 1, 2-[[2-(N-isobutyl-N-methyl)amino]benzylsulfinyl]benzimidazole shows antimicrobial activity of MIC in the range of 12.5-50 µg/mL against the standard strains as well as wild strains, which is comparable to Omeprazole, that is, the known antimicrobial agent for Helicobacter pylori, while Cimetidine and Famotidine, that is, known H 2 -blocker, show low antimicrobial activity to Helicobacter pylori. The [[2-(N-isobutyl-N-methyl)amino]benzylsulfinyl]benzimidazole and its pharmaceutically acceptable salt can be administered orally to patients to treat or prevent infectious diseases caused by Helicobacter pylori. The dose may usually be about 0.1 mg/kg/day to 200 mg/kg/day. The adiministration can be done once or more a day. The dose may be either increased or decreased depending on the age, body weight, and other conditions of the patients. A variety of preparation forms can be adopted. For instance, tablets, powder, granules, capsules, troche, syrup, emulsion, soft gelatin capsules, cream, gel, paste, and spray can be utilized. For these preparations, carriers, excipients, and other known additives can be employed. As the carriers, solid carriers such as lactose, kaolin, sucrose, crystalline cellulose, starch, talc, agar, pectin, magnesium stearate, and lecithin can be mentioned. Also employable are liquid carriers such as glycerol, polyvinyl pyrrolidone, olive oil, ethanol, benzyl alcohol, propylene glycol and water. The compound of the invention can be also adminstered in combination with other antimicrobial agents such as antibiotics. The preparation examples are given below. The active compound means [[2-(N-isobutyl-N-methyl)amino]benzylsulfinyl]benzimidazole of the invention. PREPARATION EXAMPLE 1 [Capsules] The below-mentioned composition was mixed and charged into a hard gelatin capsule to give a capsulated agent. (1) Active compound 40 mg/capsule (2) Lactose 200 (3) Starch 50 (4) Polyvinylpyrrolidone 2 (5) Crystalline cellulose 35 Total 350 mg/capsule PREPARATION EXAMPLE 2 [Tablets] The below-mentioned composition was granulated in an aqueous povidone solution, and to the granuates was added magnesium stearate and pressed to give a tablet. (1) Active compound 50 mg/tablet (2) Lactose 103 (3) Starch 50 (4) Magnesium stearate 2 (5) Hydroxypropylcellulose 15 Total 220 mg/tablet

Claims: Use of 2-[[2-(N-isobutyl-N-methyl)amino]benzylsulfinyl]benzimidazole for the manufacture of a medicament for treating or preventing infections caused by Helicobacter pylori. Use of 2-[[2-(N-isobutyl-N-methyl)amino]benzylsulfinyl]benzimidazole for the manufacture of a medicament for inactivating Helicobacter pylori.

Inventors: MASAKI MITSUO, MATSUKURA HITOSHI, NOMURA YUTAKA, YAMAKAWA TOMIO, MASAKI, MITSUO, MATSUKURA, HITOSHI, NOMURA, YUTAKA, YAMAKAWA, TOMIO
Applicants: NIPPON CHEMIPHAR CO, NIPPON CHEMIPHAR CO., LTD.
Application year: 1994
Main classification: A61K31
IPC codes: A01N43, A61K31